Bookmark and Share
BioAssay: AID 602450

qHTS Assay for Inhibitors of Influenza NS1 Protein Function: Viral Replication TCID50 SAR for Probe

Influenza is a world-wide public health problem and emerging forms of the virus have the potential to cause a pandemic of equal or greater magnitude to the outbreaks recorded in 1918, 1957 or 1968. Vaccine development is proceeding and there also exist two classes of anti-influenza compounds. However these therapeutic modalities are neither fully effective nor widely enough available to fulfill more ..
_
   
 Tested Compounds
 Tested Compounds
All(5)
 
 
Active(5)
 
 
 Tested Substances
 Tested Substances
All(5)
 
 
Active(5)
 
 
AID: 602450
Data Source: NCGC (NS1702)
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2012-03-21
Hold-until Date: 2013-03-19
Modify Date: 2013-03-19

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 5
Related Experiments
AIDNameTypeComment
2336Summary Assay for Inhibitors of Influenza NS1 Protein FunctionSummarydepositor-specified cross reference: Summary AID
2326qHTS Assay for Inhibitors of Influenza NS1 Protein FunctionConfirmatorysame project related to Summary assay
492980Assay for Inhibitors of Influenza NS1 Protein Function: Hit ValidationConfirmatorysame project related to Summary assay
504647Assay for Inhibitors of Influenza NS1 Protein Function: Influenza virus replication assay in MDCK cells infected with virus A/PR/8/34Othersame project related to Summary assay
602452qHTS Assay for Inhibitors of Influenza NS1 Protein Function: SAR Using NS1 and pYES strainsOthersame project related to Summary assay
602454qHTS Assay for Inhibitors of Influenza NS1 Protein Function: Viral Replication TCID50Othersame project related to Summary assay
602456qHTS Assay for Inhibitors of Influenza NS1 Protein Function: RT-PCROthersame project related to Summary assay
623997qHTS Assay for Inhibitors of Influenza NS1 Protein Function: Mammalian Cell ViabilityOthersame project related to Summary assay
Description:
Influenza is a world-wide public health problem and emerging forms of the virus have the potential to cause a pandemic of equal or greater magnitude to the outbreaks recorded in 1918, 1957 or 1968. Vaccine development is proceeding and there also exist two classes of anti-influenza compounds. However these therapeutic modalities are neither fully effective nor widely enough available to fulfill global needs. In addition their potential usefulness against newly emergent strains is not known. Efforts are needed to develop novel agents against influenza virus, including broad-spectrum agents. Identification of small molecules that inhibit NS1 function either directly or by interfering with specific cellular pathways may be a key to increasing our defense against the virus.

We have miniaturized and optimized a cell based assay in which NS1 from influenza A is expressed in the budding yeast S. cerevisiae. NS1 is a multi-functional protein that counters the host innate immune response and facilitates viral versus cellular gene expression. Expression of NS1 causes a pronounced slow growth phenotype in yeast due to its intrinsic molecular activities. Small molecules that suppress the slow growth phenotype can be identified by a straightforward growth recovery assay using optical density (OD) as the measurement. The same yeast strain not expressing NS1 was used as positive control in the yeast growth recovery assay.

Hits resulting from this primary screen and other follow-up screens, were tested in two concentrations in this viral replication assay.
NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Centers Network [MLPCN]

MLPCN Grant: MH084878
Assay Submitter (PI): Daniel Engel, University of Virgina
Protocol
Cell monolayers were infected at an m.o.i. of 0.1 for 48 h in the presence or absence of the compound, which was added at the beginning of infection. Virus titres were determined by TCID50 analysis (Reed, L. J. & Muench, H. (1938). A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27, 493-497).
Comment
Compounds that had a true TCID50 at 4.99 uM <= 5.5 are considered "active"; compounds are "inconclusive" if > 5.5 and < 6.5 at 4.99 uM; and "inactivity" if true TCID50 >= 6.5 at 4.99 uM.

"Active compounds are assigned a score of 90, "inconclusive" 50, and "inactive" 10.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1TCID50 at 0.05 uMFloat
2TCID50 at 0.165 uMFloat
3TCID50 at 0.5 uMFloat
4TCID50 at 1.65 uMFloat
5TCID50 at 4.99 uMFloat
6IC90 (uM) FloatμM
7Compound QCString
Additional Information
Grant Number: MH084878

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: